BRAF and colorectal carcinoma: To determine if the limited effect of BRAF inhibitors on apoptosis extended to the clinically relevant encorafenib+cetuximab (Enc+Cet) combination, we treated the five BRAFV600E CRC cell lines with Enc+Cet.